Assays for Vaccine Development and Testing
Best-in-Class Services for COVID-19, Flu, and Other Infectious Diseases
At Nexelis, a Q² Solutions Company, we approach each vaccine program with disciplined agility: scientific excellence and full transparency with the flexibility, ingenuity, and capacity for the quick decision-making needed. Our expertise is built on a foundation of 20 years of experience in vaccine efficacy and safety evaluation as a partner to industry leading vaccine manufacturers worldwide. Cutting-edge technology platforms and state-of-the-art laboratories enable us to best develop, qualify, and validate single and multiplex immunological assays and sample testing to support vaccine development.
Nexelis has seven integrated platforms that help you progress from vaccine development through clinical evaluation. Our main focus is on the evaluation of the efficacy of the vaccine — be it in the developmental stages or in clinical immunological responses. Critical reagents and well-established assays are indispensable to the efficient assessment of vaccine candidates. We take pride in our ability to develop innovative and critical reagents in-house. This capacity allows us to scale rapidly and helps control batch-to-batch variations of assay materials — crucial factors in maintaining operational excellence, high quality data, and world class science for our clients.